Objective To generally analyse the current situations and advances in the biotherapy of gastric cancer. Methods The published papers about the current situations and research advances in the biotherapy of gastric cancer were reviewed.Results The main research fields and treatments in the biotherapy of gastric cancer include immunomodulator therapy, guided therapy of monoclonal antibodies and their joint-bodies, cytokine therapy, adoptive immunotherapy and gene therapy, etc. Conclusion As a beneficial complement for surgery, chemotherapy and radiotherapy, biotherapy plays an important auxiliary role in the multiple treatments for gastric cancer.

As a guanine nucleotide dissociation stimulator (GDS) of Rho-like GTPases, T lymphoma invasion and metastasis inducing factor 1(Tiam 1)possesses such biological functions as regulating reconstruction of cytoskeletal structure and migratory potential of cells. Studies had shown that over-expression of Tiam 1 was able to induce invasion and metastasis of tumor cells, the molecular biological basis of which includes the interactions between Tiam 1 and trans-membrane system of cytoskeleton, adhesion molecules and extra-cellular matrix, the effect on proliferation and apoptosis of tumor cells exposed by Tiam 1, as well as the activities of Tiam 1 regulated by other invasion and meatstasis associated factors. Simultaneously, these experimental results suggested that much more work would be needed in Tiam 1 on the diversity of its activity regulation ,the specificity of its biological effect, the realationship among Tiam 1 with other invasion and metastasis associated factors, as well as their mechanisms of signal transduction.

With the development of image technology,functional imaging was gradually applied to contouring the gross target volume,which generated the concept of biological target volume and biological intensity-modulated radiation therapy.In this review,we introduced our work and the current status of ~(18)F-fluorodeoxyglucose imaging,amino acids imaging,nucleic acid imaging,hypoxic imaging,gene imaging and molecular imaging.The future of functional imaging and it application in biological intensity-modulated radiation therapy were discussed in prospect.

Primary lung cancer is one of the most common malignant tumors in China.The 2015 Edition of primary lung cancer diagnosis and treatment norms was updated based on 2010 Edition.This 2015 edition was published by the National Health and Family Planning Commission,which has referenced to the international authority of the lung cancer treatment guidelines and the actual situation of China.This paper mainly introduces the new content of lung cancer radiotherapy,including radical radiotherapy,palliative radiotherapy,adjuvant radiotherapy and preventive radiotherapy.

Cancer prevention and treatment have developed from evidence-based model into personalized model.Precise medicine has been developed in recent years.It is very important to incorporate personalized and precise idea into clinical practice and makes it accepted by the public.It is also a long way to go to provide precise service for numerous cancer patients through the research using special resource of our country.

Angiotensin-(1-7)[Ang-(1-7)]is an endogenous peptide-hormone of the renin-angioten-sin system. Ang-(1-7),angiotensin-converting enzyme 2( ACE2)and MAS receptor constitute ACE2-Ang-(1-7)-Mas axis,which antagonizes the ACE-AngⅡ-AngⅡ type 1 receptor axis. Recent studies indicate that Ang-(1-7)has certain effects on treating tumors,including inhibition of angiogenesis,anti-cell proliferation and inhibition of tumor fibrosis. Researches on the roles and mechanisms of Ang-(1-7)can provide new target for treatment and prevention of cancer.

3′-deoxy-3′-18F-fluorothymidine has been described recently as a new positron emission tomography (PET) tracer for imaging tumor cell proliferation. In recent years, more and more clinical research demonstrate that 18F-FLT can image tumor cell proliferation during treatment, and can reflect accelerated reproliferation earlier. it can define tumor subvolumes with high proliferative activity preceding volumetric tumor response, and can predict relapse and prognosis according to the changing status during the treatment.

The effects of radiotherapy (RT) on the survival of cancer patients are interpreted as a consequence of the improved lo-cal control of tumors that directly decrease systemic spreading. Some of the effects of ionizing radiation are recognized as a contribu-tion to systemic antitumor immunity, which can provide sufficient evidence for proposing a paradigm shift. Recent examples of objec-tive responses achieved by adding radiotherapy to immunotherapy in metastatic cancer patients support this view. Preclinical data indi-cate that RT can convert irradiated tumor into an in situ individualized vaccine and potentiate the systemic efficacy of immunotherapy, whereas activation of the innate and adaptive immune system can enhance the local efficacy of RT. This study summarizes key evi-dence that support the role of radiotherapy as an immune adjuvant and some of the current challenges in translating this knowledge for clinical use.

[Objective] To investigate the effect of Dengzhan Xixin Injection (DXI) combined with photon-autotransfusion therapy in treating diabetic peripheral neuropathy (DPN). [ Methods ] Sixty-one cases of DPN were randomized into 2 groups. Group A ( n=31) was given DXI 30 - 40 mL (intravenous drip, qd) and photon-autotransfusion therapy (once every 2-3 days). Group B (n = 30) was treated with anisodamine 10 - 20 mg (intravenous drip, qd) and vitamin B] 100 mg and B12 500 ?g (intramuscular injection, qd) . Changes of symptoms and signs and neural conductive velocity were observed to evaluate the curative effect after treatment. [ Results ] The markedly effective rate and total effective rate were 58.07% and 93.55% respectively in group A, which were higher than those in group B (16.67% and 63.34% respectively) , the difference being significant ( P

Objective To assess the early response and acute side effects of late course stereotactic radiosurgery (LCSR) for stage Ⅲ b lung squamous cell carcinoma. Methods From June 1997 to July 1999, 136 patients with stage Ⅲ b squamous cell carcinoma of lung were treated with the conventional radiotherapy of 40 Gy followed by LCSR to the residual lesion. Stereotactic radiosurgery was given in the 5～6th weeks, 5～8 Gy per fraction with the total doses ranging from 24 to 38 Gy. Results Five patients were excluded from this study due to distant metastases and acute complications. The remaining 131 patients were analyzed to evaluate the early responses and acute complications. Acute radiation induced esophagitis occurred in 41.2% of patients (Grades Ⅰ Ⅱ (RTOG), 4.4% Grade Ⅲ). Acute radiation induced pneumonitis was observed in 16.9 % of patients ( Grades Ⅰ Ⅱ (RTOG),5.2% Grade Ⅲ). The overall response rate (CR+PR) was 86.3% for the primary tumor, and 92.4% for metastatic mediastinal lymph nodes. Conclusions LCSR is well tolerated in most patients with stage Ⅲ b squamous cell carcinoma of lung. The early responses of LCSR in the of tumor are better than the conventional radiotherapy.Remote results await further follow up.